Delivery Order SPE2DB22D2206-SPE2DB25FJF80
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ONIVYDE 43 mg/10 ml vials, with a firm fixed price ceiling value of $10,691.34 and an ultimate completion date of October 8, 2025. This non-set-aside, competitively awarded delivery order is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $5,403.30 to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, on August 4, 2025. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by August 5, 2025. The award was made through competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency's Medical Supply Chain issued a delivery order valued at $7,111.19 to AmerisourceBergen Drug Corp on August 25, 2025, for pharmaceutical and medical supply deliveries to be completed by August 26, 2025. This competitively awarded, firm fixed-price delivery order was placed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The delivery order...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $17,139.14 to AmerisourceBergen Drug Corp on April 22, 2025, with completion scheduled for April 23, 2025. This firm fixed price, non-set-aside delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $8,744.16 to AmerisourceBergen Drug Corp for the supply of Onyda XR 0.1 mg/ml suspension (30ml) on August 5, 2025, with completion scheduled for August 6, 2025. This non-competitive, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,617.86 to AmerisourceBergen Drug Corp on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order, issued without a set-aside designation, procures pharmaceutical products identified as "4569419801 ! DT 1C 2.25X4 700/RL 6RL/BX DHAPCL" for delivery to Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $2,167.54 to AmerisourceBergen Drug Corp on September 8, 2025, for pharmaceutical products under a firm fixed-price contract. This competitively awarded delivery order, with an ultimate completion date of September 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the vendor's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,404.40 by the Defense Logistics Agency's Medical Supply Chain on July 21, 2025. The contract is structured as a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-competitive award under an existing indefinite delivery contract vehicle. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,552.64 to AmerisourceBergen Drug Corp on April 24, 2025, for pharmaceutical and medical supply products. This firm fixed-price delivery order, issued under a non-competitive set-aside arrangement, is set to be completed by April 25, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $9,974.65 by the Defense Logistics Agency's Medical Supply Chain on July 4, 2025, with an ultimate completion date of July 7, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the company's extensive federal pharmaceutical supply portfolio. The delivery order is...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJF80Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,127.56 to AmerisourceBergen Drug Corp for the supply of Onivyde 43 mg/10 mL vials. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain. The company's extensive portfolio includes specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support military healthcare systems and other government agencies including the Defense Health Agency and U.S. Coast Guard. This particular delivery order for Onivyde, a specialized oncology medication, exemplifies the company's role in supplying critical pharmaceutical commodities through DLA's competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 8/5/25 |